Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · Randomized Controlled Trials

The Randomized Controlled Trial: Randomization, Allocation Concealment and Good Clinical Practice

Randomisation does not guarantee the two groups in a trial are identical. It guarantees that any difference between them, beyond the treatment itself, is due to chance rather than to anyone's choice -- which is a very different, and much more useful, guarantee.

Pubrica AcademyWritten by a clinical-trials reviewer Reviewed bya biostatistician Published10 October 2026 Last checked10 October 2026 Reading time8 minutes Sources2 peer-reviewed

A randomized controlled trial (RCT) is a study in which participants are allocated to an intervention or a comparator by a chance-based process, so that known and unknown factors influencing the outcome are, on average, distributed evenly between groups, isolating the effect of the intervention itself from systematic differences in who received it.

Learning objectives

  • Why allocation by chance is what distinguishes a randomized controlled trial (RCT) from other comparative designs.
  • What allocation concealment is, and why it is a distinct requirement from randomisation itself.
  • How Good Clinical Practice defines the conduct standards an RCT is expected to meet.
  • Why randomisation addresses confounding but not every source of bias in a trial.

Common misconceptions

  • “Any study comparing two groups that received different treatments is a randomized trial.” A trial is randomized specifically because allocation to each group was determined by a chance-based process rather than by clinician or patient choice; this is precisely the feature that distinguishes it from the observational designs discussed in the Academy article on observational study designs.
  • “Randomisation alone guarantees a trial is free of bias.” Randomisation addresses confounding by balancing known and unknown factors between groups on average; it does nothing on its own to prevent bias from inadequate blinding, differential loss to follow-up, or outcome-assessment bias, which require separate design safeguards.

Chance-based allocation as the defining feature

The defining feature of a randomized controlled trial is that the process allocating participants to the intervention or comparator group is based on chance, specified in advance by the trial's protocol, rather than determined by the treating clinician's judgement, the patient's preference, or any other non-random factor. Because the allocation is chance-based, both known confounding factors (such as age or disease severity) and unknown ones are expected, on average across a sufficiently large trial, to be balanced between groups, which is what allows a difference in outcome between groups to be attributed to the intervention rather than to pre-existing differences between the people who received it.

Allocation concealment as a distinct requirement

Randomisation and allocation concealment are related but distinct requirements, and the CONSORT statement's items on randomisation make this distinction explicit: a trial can use a genuinely random sequence to generate allocations, but if the person enrolling participants can predict or influence which allocation a given participant will receive before it is assigned, the randomisation's balancing effect can be undermined by selective enrolment. Allocation concealment -- keeping the upcoming allocation from whoever enrols participants until after enrolment -- is the specific design feature that protects randomisation's intended effect from this risk.

Good Clinical Practice conduct standards

Clinical trial procedures should follow the applicable ICH E6(R3) Good Clinical Practice guidance and local regulatory requirements. ICH Good Clinical Practice guidance sets out the conduct standards an RCT testing an investigational product is expected to follow, covering trial design, investigator responsibilities, informed consent, data handling, and monitoring, alongside the protection of trial participants. These conduct standards exist alongside, not instead of, the statistical logic of randomisation itself -- a trial can be correctly randomised and still fail to meet the ethical and procedural standards GCP requires, which is why both are assessed separately when a trial's quality is reviewed.

Key points

Key points

A randomized controlled trial's defining feature is chance-based allocation to intervention or comparator, which balances known and unknown confounders between groups on average -- but allocation concealment is a distinct, necessary safeguard for that balancing effect, and Good Clinical Practice conduct standards govern the trial's ethical and procedural execution separately from its statistical design.

Practical application

Practical application

  1. The randomisation method and the concealment mechanism should be stated separately. Authors should describe both how the random sequence was generated and how allocation was concealed from those enrolling participants, since these are distinct items that reviewers check independently.
  2. The trial should be designed to Good Clinical Practice conduct standards from the outset. Informed consent, monitoring and data-handling procedures should be developed in line with the applicable ICH E6(R3) Good Clinical Practice guidance and local regulatory requirements during protocol development rather than retrofitted after enrolment begins.
  3. Reporting should state what randomisation does and does not address. The discussion should state explicitly which potential biases randomisation addresses (confounding) and which it does not (such as outcome-assessment bias in the absence of blinding), rather than treating randomisation as a general guarantee of validity.

Frequently asked questions

Randomized trials are generally considered stronger for establishing causal effects because of their confounding control, but they are not immune to bias from other sources, and a well-conducted observational study can sometimes answer questions an RCT cannot ethically or practically address.

Randomisation determines how participants are allocated to groups; blinding concerns who knows which group a participant is in after allocation -- the two address different potential sources of bias and are reported as separate items.

Yes; an open-label randomized trial is randomized but not blinded, which is sometimes unavoidable (for example, when comparing a surgical intervention to a non-surgical one) and should be disclosed as a limitation.

References

  1. International Council for Harmonisation. ICH Harmonised Guideline E6(R2): Good Clinical Practice. read 10 October 2026. View ICH E6(R2) guideline (PDF)
  2. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. read 10 October 2026. View on The BMJ

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). The Randomized Controlled Trial: Randomization, Allocation Concealment and Good Clinical Practice. Pubrica. https://pubrica.com/academy/concepts-definitions/randomized-controlled-trials/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

RCT design and conduct checklist stub

Use when designing or reviewing a randomized controlled trial.

[ ] Random sequence generation method stated
[ ] Allocation concealment mechanism stated
[ ] Blinding status (participants, clinicians, assessors) stated
[ ] Good Clinical Practice conduct elements (consent, monitoring, data handling) addressed
[ ] Confounding vs. other bias sources distinguished in discussion

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s clinical-trials team designs randomisation and allocation-concealment procedures to Good Clinical Practice standards and prepares the methods section to the level of detail expected by CONSORT and by statistical reviewers.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Designing and reporting randomized controlled trials to withstand peer review

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.